Roche punts a PhI can­cer drug out of the pipeline and back to Ory­zon

Lit­tle Ory­zon Ge­nomics in Spain picked up a con­sid­er­able en­dorse­ment and fi­nan­cial sup­port when Roche stepped in three years ago to part­ner on its ly­sine spe­cif­ic demethy­lase-1 (LSD1) in­hibitor ORY-1001 (RG6016) for acute my­loid leukemia and sol­id tu­mors. But it had to give up the deal and the $500 mil­lion in mile­stones that came with it af­ter Roche de­cid­ed to punt it out of the pipeline.

Ac­cord­ing to Ory­zon, the drug didn’t make the cut at the Swiss phar­ma gi­ant as it “repri­or­i­tized” its pipeline. Roche will see through an on­go­ing Phase I study in small cell lung can­cer and then hand it all back to Ory­zon, which plans to car­ry on with the work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER